This might help from Alan Osmonds website.
October 5, 2007
Today I was informed that Argyll Biotechnologies New Website is now available at: http://www.argyllbiotechnologies.com/
(link is above)
You can learn more about the product that has helped me so much! It is called SF-1019 !!!
There were other threads here which made it clear that SF1019 and Aimspro are different products.
A Statement from the Daval Website.
http://www.davalinternational.com/index ... php?nid=14
24/10/06 - "Aimspro" in Mexico
It has been brought to our attention that MS chat-lines are referring to a product administered in Mexico as Aimspro. Please note that Aimspro is a registered Trade Mark for a product distributed for Daval International Limited in the United Kingdom, which is manufactured under conditions approved by regulatory agencies.
The product which is reported to be available in Mexico is definitely not Aimspro. It is therefore an imitation of doubtful provenance and its regulatory standing is suspect.
The link from Alan Osmonds site leads here
SF-1019 is the platform technology of Argyll Biotechnologies. It was developed from extensive research into Biological Response Modifiers (BRMs) undertaken at: Mississippi State University; St George's, University of London (formerly St George's Hospital Medical School); Ohio University; and Methodist Hospital. The first group of BRMs was designated as Immune Cell Potentiating Factors (ICPF) and has been extensively evaluated in a number of veterinary treatments, including animal studies relating to human disease. This collaborative approach brought the thorough and unbiased scrutiny of the scientific and medical community upon the related research and particularly SF-1019. In our opinion, these data collectively support the conclusion that SF-1019, as a BRM, may point the way for the future development and refinement of many promising innovative and cutting-edge therapeutics.
SF-1019 is believed to be one of a new class of therapeutics made from mammalian cells. As an isolated compound, SF-1019 is comprised of low molecular weight lipo-peptides. Pre-clinical human studies and clinical trials in animals have shown SF-1019 to provide therapeutic benefits without toxic or pyrogenic (fever-causing) effects at therapeutically effective dosages. In animal studies, once injected subcutaneously, SF-1019 produces an immunomodulatory cascade, which generates a prophylactic and/or therapeutic benefit. In pre-clinical human studies, it appears to create a therapeutic affective response over a range of demyelinating conditions of the peripheral nervous system (PNS) resulting in rapid reduction of symptoms. A major benefit of SF-1019 is its perceived ability to simultaneously target, activate and support the modulation of both the innate and adaptive immune systems, having a dramatic effect on many neurological and demyelinating conditions. Research suggests the current product has additional developmental potential as it also possesses analgesic properties with an ability to substantially reduce the inflammation attending a number of clinical conditions including Multiple Sclerosis (MS), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Reflex Sympathetic Dystrophy Syndrome, (RSD or RSDS) and other auto-immune and neurological disorders.
Patent applications containing claims to Argyll Biotechnologies’ proprietary biological response modifier SF-1019 have been filed in selected countries around the world. Those applications have been receiving favorable review with one or more patents expected to issue in 2007. Additional patents are expected soon thereafter.
Argyll Biotechnologies has initiated the approval process in several countries and preparations for clinical trials in humans are underway in both the US and Europe with plans to develop a series of new products from Argyll Biotechnologies’ proprietary platform technology and other licensed techniques. These trials are the first of a planned new SF-1019 based product series designed to treat or improve the quality of life and the clinical management of a number of auto-immune and neurological disorders and other human diseases. Argyll Biotechnologies will continue to pursue regulatory approval for SF-1019 with the compassionate goal of SF-1019 potentially becoming a first line defense for mainstream medical practitioners.
Argyll Biotechnologies has transferred to Immunosyn Corporation the world-wide rights to market and distribute SF-1019 by way of an exclusive licensing agreement.
Immunosyn also has a website here
It does seem to me that SF1019 is not yet a licensed product and if it is freely available in Utah then all is not well. Could it be that others have done the same as Alan Osmond and obtained a legal supply from Mexico?.
Keep smiling as who knows what good things might be around the corner and if the road snakes a bit keep going.